News Contact Us

Cipla launches generic version of Remdesivir at a price of ₹4,000

Author : Pankaj Singh | Published Date : 2020-07-10 

Cipla Limited, the multinational pharmaceutical company, has reportedly launched a generic version of the remdesivir drug (Cipremi) at a price of ?4,000 per 100 mg vial, making it among the least priced COVID-19 treatment available across the globe.

According to sources familiar with the knowledge of the matter, the company is looking to supply more than 80,000 vials within the first month. The company's move to introduce remdesivir drugs at ?4,000 per 100 mg vial price is in line with its philosophy of accelerating access and affordability. The drug will be available only through hospital and government channels to ensure equitable distribution.

Till now, remdesivir is the only drug treatment approved by the US FDA (Food and Drug Administration) under EUA (Emergency Use Authorization) for treating hospitalized COVID-19 patients.

Speaking on which, Cipla CEO and Executive VP Nikhil Chopra (India Business) said in the statement that the company is proud to introduce Cipremi today which is amongst the lowest priced drug globally. The company is aiming to supply more than 80,000 vials within the first month itself, states Mr. Chopra.

Mr. Chopra added that the company would be donating some amount of the drug as part of its efforts to aid the community in this time of need.

The DCGI (Drug Controller General of India) approved Cipla’s remdesivir for restricted emergency use in the nation as part of the faster approval process considering the unmet and urgent medical need. In May, regional Pharma companies Jubilant Life Sciences, Hetero, and Cipla entered into non-exclusive licensing agreements with Gilead Sciences Inc for manufacturing and distributing remdesivir in the nation.

Meanwhile, India’s first potential COVID-19 vaccine, Covaxin will soon enter human clinical trials. Developed by Hyderabad- based Bharat Biotech, the vaccine will be tested on more than 1,100 people in two phases. The company already announced the plan to register 375 participants to test the COVID-19 vaccine candidate this month.

Source Credit -https://www.livemint.com/news/india/coronavirus-vaccine-cipla-launches-generic-version-of-remdesivir-in-india-11594223346722.html

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Alaska Airlines mandates ‘no mask no travel’ policy for passengers

Published Date: 2020-08-07         Author: Pankaj Singh

Alaska Airlines, a Washington-based airline major, has recently announced that passengers over the age 2 years would be required to compulsorily wear face covering or cloth mask over their mouth and nose as a safeguard against the contagious COVID-19 disease. Reportedly, passenger that do not adh... Read More

E-learning startup Byju's nears $400 million funding from DST Global

Published Date: 2020-08-05         Author: Pankaj Singh

The lockdowns and the practice of social distance across India have prompted students to opt for online learning. As digital learning takes center stage during this challenging time, e-learning companies like Think & Learn Pvt. Ltd.( Byju's), Unacademy, and Vedantu have been taking proactive... Read More

MAS grants SRFB privileges to StanChart under improved framework

Published Date: 2020-08-03         Author: Pankaj Singh

The Monetary Authority of Singapore (MAS), Singapore’s financial and central bank authority has reportedly awarded SRFB (Significantly Rooted Foreign Bank) privileges to Standard Chartered Singapore, which allows the bank to operate in additional places of business. The agency said in the p... Read More

© 2020 Fractovia. All Rights Reserved